Position in EXEL
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$1,475,000
+$341,032 QoQ
Shares Held
27,109
+2.5% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#299
of 756 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GRANDFIELD & DODD, LLC holds $46,143,038 across 12 Biotechnology names. EXEL ranks #5 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
36,628 | $22,839,023 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
24,838 | $12,337,779 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
37,077 | $2,939,835 | |
| 4 | INCY |
Incyte Corp
|
20,822 | $2,360,381 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
27,109 | $1,475,000 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
18,243 | $1,043,864 | |
| 7 | GMAB |
Genmab A/S
|
37,633 | $1,033,778 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,204 | $964,500 |
All Filings in EXEL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,475,000 | 27,109 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $1,133,968 | 26,439 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $1,186,434 | 27,069 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $1,115,141 | 27,001 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $1,163,756 | 26,401 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $972,140 | 26,331 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $728,137 | 21,866 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $311,919 | 12,020 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||